N- ((1- ((5- (4- fluorophenyl)- 2- methyl- 4- thiazolyl)carbonyl)- 2- piperidinyl)methyl)- 4- benzofurancarboxamide

08/01/2012 - "Multicenter, randomized, double-blind, placebo-controlled crossover study using a complete set of Williams orthogonal Latin Squares 9 sleep centers in Germany 52 male subjects with a diagnosis of primary insomnia (difficulty in sleep initiation and maintenance) confirmed by polysomnography SB-649868 (10, 30, 60 mg) and placebo administered after dinner 90 minutes before bedtime Sleep effects assessed by polysomnography during 2 consecutive nights and by sleep questionnaires completed by subjects after each night at the sleep laboratory. "
08/01/2012 - "To assess the acute effects of SB-649868 in male subjects with Primary Insomnia with regard to (1) objective and subjective sleep parameters, (2) safety and tolerability, (3) next-day residual effects. "
08/01/2012 - "The data demonstrate the sleep-promoting properties of the orexin antagonist SB-649868 in male patients with insomnia."
08/01/2012 - "The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia."
11/01/2014 - "Several compounds (almorexant, SB-649868, suvorexant) have been in advanced clinical trials for treating primary insomnia. "

08/01/2012 - "Results of these trials support further investigation of SB-649868 and other dual orexin receptor antagonists as potentially effective and well-tolerated treatments for patients with sleep disorders."
08/01/2012 - "This paper describes initial Phase I trials of a novel dual orexin receptor antagonist SB-649868 that has demonstrated preclinical potential for treatment of sleep disorders. "
01/01/2013 - "Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, SB-649868, suvorexant (MK-4305), and filorexant (MK-6096), have shown promise for the treatment of insomnias and sleep disorders. "

10/01/2014 - "Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans."

08/01/2012 - "Therefore, the effects of GSK1059865 (5-bromo-N-[(2S,5S)-1-(3-fluoro-2-methoxybenzoyl)-5-methylpiperidin-2-yl]methyl-pyridin-2-amine), a selective OX(1)R antagonist, JNJ-10397049 (N-(2,4-dibromophenyl)-N'-[(4S,5S)-2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl]urea), a selective OX(2)R antagonist, and SB-649868 (N-[((2S)-1-{[5-(4-fluorophenyl)-2-methyl-1,3-thiazol-4-yl]carbonyl}-2-piperidinyl)methyl]-1-benzofuran-4-carboxamide), a dual OX(1)/OX(2)R antagonist were evaluated in a binge eating (BE) model in female rats. "